DD

Business profile & competitive position

DuPont de Nemours, Inc. (DD) is classified in the Basic Materials / Chemicals industry. Today it operates as a provider of advanced materials and components serving healthcare, water, construction, and industrial end markets. Following its recent portfolio reshaping, the company reports through two segments: Healthcare & Water Technologies and Diversified Industrials. The continuing operations supply products such as medical packaging and devices, water filtration and purification systems, building-envelope and interior solutions, industrial adhesives, lubricants, engineered shapes, and printing plates. The Electronics, Aramids, and historical M&M businesses are treated as discontinued operations.

Its most recent financials show a net margin of 0.7% and ROE of 0.3%. Those figures are extremely low for a company of this scale and indicate that, on a trailing basis, DuPont is barely converting revenue into shareholder profit. A chemicals business with durable pricing power and a wide competitive moat would normally command double-digit margins and mid-teens ROE; the current 0.7% / 0.3% profile instead points to a transitional company carrying restructuring charges, discontinued-operation impacts, and/or ongoing litigation costs that are compressing reported returns. That alone does not prove the moat is gone, but it does show the current income statement is not reflecting strong, sustained pricing power.

Financial posture

As of the snapshot date, DuPont carried a $16.7 billion market cap, traded at $123.33, and posted a trailing P/E of 268.1. The P/E is far above typical chemicals-sector multiples, which is consistent with the 0.7% net margin: earnings are depressed, so a modest absolute stock price translates into a very high multiple. In other words, the market is not valuing DuPont off current net income; it is pricing in a much higher normalized earnings stream after divestitures, buybacks, and litigation resolution.

Profitability metrics remain weak. The 0.7% net margin and 0.3% ROE do not support a premium multiple on a trailing basis. The stock’s beta of 1.08 is essentially market-like, so there is no strong risk-off or risk-on embedded in the price behavior relative to the broad market. Near-term technicals show the stock well below its 50-day EMA of $136.48, with an RSI of 24.2 — a reading below 30 that technicians generally associate with short-term oversold conditions.

Strategic priorities & outlook

DuPont’s most recent 10-K frames the company around two core priorities: completing the transformation of the portfolio and returning capital to shareholders.

• Aramids divestiture: The company expects to complete the previously announced sale of the Aramids business to Arclin around the end of the first quarter of 2026, pending closing conditions and regulatory approvals. The Aramids business employed roughly 1,700 of DuPont’s approximately 15,000 global employees.
• Electronics separation: Management is focused on realizing the intended tax treatment and contractual liability allocations tied to the Electronics separation, which was executed through Qnity.
• Capital return: The company announced a $2 billion share buyback authorization on November 6, 2025, and executing that program is listed as a near-term priority.
• PFAS cost sharing: DuPont is managing a cost-sharing arrangement with Corteva and Chemours that covers future eligible PFAS costs, including litigation and remediation exposures.

Operationally, the 10-K also notes that effective the fourth quarter of 2025, DuPont recast its financial statements as if the M&M, Aramids, and Electronics separations had occurred on January 1, 2023, and it now reports through the two continuing-operations segments. The company held about 6,100 patents and patent applications globally, with roughly 4,700 associated with continuing operations, and more than 70% of the continuing-operations patent estate had a remaining term of more than five years.

Macro & geopolitical exposure

As a Basic Materials / Chemicals company with operations in about 20 manufacturing countries and subsidiaries in about 50 countries, DuPont is exposed to the standard macro toolkit: energy and feedstock prices, freight and logistics costs, currency translation, and industrial demand cycles. Chemicals producers are also among the most directly affected by environmental regulation, emissions rules, and product-safety litigation. PFAS is the single most visible liability theme for this industry, because “forever chemicals” claims can generate large remediation and settlement payments across multiple jurisdictions. Trade policy matters as well: tariffs on raw materials or finished goods can move margins quickly in chemicals, where end-market pricing power varies by specialty. Finally, construction and industrial demand are cyclical, while healthcare and water exposure provides some defensive, non-discretionary demand offset.

Recent developments

The latest news flow has been dominated by portfolio and litigation developments:

• On September 13, 2026, defenseworld.net reported that Capital Analysts LLC had cut its stake in DuPont de Nemours.
• On September 10, 2026, multiple outlets covered PFAS settlements tied to North Carolina contamination. BusinessWire reported a $380 million settlement secured by Baron & Budd with DuPont, Chemours, and Corteva, while Reuters cited a combined $455 million settlement among Chemours, DuPont, and Corteva to resolve North Carolina “forever chemicals” claims. PRNewswire also reported that the three companies reached an agreement to resolve PFAS-related claims in the state.

These settlements are directly tied to the PFAS cost-sharing arrangement DuPont flagged in its 10-K. While the headline numbers capture investor attention, the more important operational point is how ongoing eligible PFAS costs are allocated among DuPont, Corteva, and Chemours going forward, because that sharing mechanism will influence future earnings volatility.

Earnings behavior & post-earnings drift

DuPont has beaten earnings estimates in 8 of its last 8 reported quarters, a 100% beat rate, with an average earnings surprise of 171.1%. Over the five trading days following each of those reports, the stock has averaged a +2.83% drift, classified as upward drift.

The last four quarters illustrate both the consistency and the skew in the surprise figures:

• August 4, 2026: actual EPS of $1.88 versus estimate $1.76, a 6.8% surprise. The stock rose 3.11% the next day and 1.09% over the following five days.
• May 5, 2026: actual EPS of $1.65 versus estimate $0.4881, a 238% surprise. The stock gained 1.69% the next day and 2.64% over the next five days.
• February 10, 2026: actual EPS of $1.38 versus estimate $1.29, a 7% surprise. The stock moved up 4.25% the next day and 3.88% over the following five days.
• November 6, 2025: actual EPS of $3.27 versus estimate $0.4656, a 602.3% surprise. The stock rose 1.66% the next day and 3.70% over the next five days.

The extremely large average surprise is driven partly by low baseline estimates rather than purely explosive growth. Still, the pattern shows that the company has consistently cleared the market’s real expectation, and the average post-earnings drift has been positive. The upcoming report is scheduled for November 5, 2026, before the open, with a consensus EPS estimate of $1.87. Based on the recent trend, the unofficial consensus appears to be priced around that $1.87 level, but the recent August quarter’s five-day drift of only 1.09% also shows that beats do not guarantee large post-report follow-through.

For a deeper dive into how institutional analysts are interpreting these same data points — including the PFAS liability, the Electronics separation, and the $2 billion buyback program — consult the full institutional verdict on the ticker page.